Study guide

6.2 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination

CIH Certified Industrial Hygienist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The CIH Exam and How to Use This Guide

1.1 CIH Exam Format, Scoring, and Test-Day Logistics 1.2 Eligibility, Application Windows, Fees, and Certification Maintenance 1.3 The BGC Blueprint, Subject Areas, and a Calculation-First Study Plan

2 Chapter 2: Basic Science & Calculations

2.1 Gas Laws and Vapor Calculations 2.2 Unit Conversions: ppm, mg/m³, and Standard Temperature/Pressure 2.3 Fluid Mechanics and Airflow Fundamentals

3 Chapter 3: Air Sampling & Instrumentation

3.1 Active and Passive Air Sampling Strategies 3.2 Particulate and Aerosol Sampling 3.3 Direct-Reading Instruments and Calibration

4 Chapter 4: Analytical Chemistry & Lab Methods

4.1 Gas Chromatography and Mass Spectrometry 4.2 High-Performance Liquid Chromatography and Ion Chromatography 4.3 Spectroscopy and Elemental Analysis 4.4 Gravimetric, Microscopy, and Wet Chemical Methods 4.5 Laboratory Quality Assurance, Chain of Custody, and Desorption Efficiency

5 Chapter 5: Biostatistics & Epidemiology

5.1 Lognormal Distributions and Exposure Data Statistics 5.2 Upper Confidence Limits (UCL95) and Compliance Decision Rules 5.3 Epidemiological Study Designs and Measures of Association 5.4 Sampling Strategy: Sample Size, Power, and Worker Selection

6 Chapter 6: Toxicology & Biological Monitoring

6.1 Dose-Response Relationships and Points of Departure 6.2 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination 6.3 Aerosol Deposition, Clearance, and Respiratory Tract Dosimetry 6.4 Hepatic, Renal, Neurologic, and Hematologic Target Organ Toxicity 6.5 Pulmonary Toxicology, Carcinogenicity, and Reproductive Hazards 6.6 OEL Frameworks, Classifications, and Excursion Limits 6.7 Chemical Mixtures and Extended Work-Shift OEL Adjustments 6.8 Biological Exposure Indices (BEIs) and Biomonitoring

7 Chapter 7: Biohazards & Indoor Environmental Quality

7.1 Mold, Fungi, and Microbial Contaminants 7.2 Infectious Agents, Bloodborne Pathogens, and Biosafety Levels 7.3 Indoor Environmental Quality (IEQ) Investigations 7.4 Sanitation, Potable Water, and Personal Hygiene Programs

8 Chapter 8: Community Exposure & Environmental Health

8.1 Clean Air Act Framework, NAAQS, and New Source Review 8.2 Hazardous Air Pollutants, CEMS, and EPA Reference Methods 8.3 Atmospheric Stability, Lapse Rates, and Plume Morphology 8.4 Gaussian Plume Modeling, Plume Rise, and Environmental Fate 8.5 HAZWOPER Scope, Mandates, and Training Tiers 8.6 Protection Levels, Site Zoning, Incident Command, and Decontamination 8.7 Water Pollution, Hazardous Waste, and Community Right-to-Know

9 Chapter 9: Health Risk Analysis & Hazard Communication

9.1 GHS Hazard Classification: Health and Physical Hazard Criteria 9.2 GHS Labels, Safety Data Sheets, and Trade Secret Rules 9.3 The AIHA Exposure Assessment Strategy and Similar Exposure Groups 9.4 Qualitative Exposure Profiling and the AIHA Risk Matrix 9.5 Quantitative Health Risk Characterization: HQ, HI, and ELCR 9.6 NIOSH Occupational Exposure Banding 9.7 Risk Communication and Reporting to Affected Parties

10 Chapter 10: Industrial Ventilation Principles & LEV Design

10.1 Elimination, Substitution, Isolation, Containment, and Process Change 10.2 LEV Hood Taxonomy and Capture Velocity Selection 10.3 Hood Airflow Equations, Entry Losses, and Hood Static Pressure 10.4 Particulate Transport Aerodynamics and Duct Sizing 10.5 Duct Friction, Fitting Losses, and System Balancing 10.6 Fan Categories and Pressure Dynamics Across the Fan 10.7 System Curves, the Fan Laws, and Density Corrections

11 Chapter 11: General Ventilation, Air Cleaning & Diagnostics

11.1 Dilution Ventilation Principles and Steady-State Modeling 11.2 Transient Purging and Air Distribution Geometry 11.3 Particulate Air Cleaning: Cyclones, Baghouses, Scrubbers, and ESPs 11.4 Gaseous Emission Control and Air Cleaner Selection 11.5 Ventilation System Troubleshooting and Testing

12 Chapter 12: Noise Measurement & Hearing Conservation

12.1 Acoustic Physics and Decibel Mathematics 12.2 Sound Propagation, Octave Bands, and Frequency Weighting 12.3 Noise Dose Metrics and OSHA versus ACGIH Criteria 12.4 Exchange Rates, Extended Shifts, and Dosimetry Field Protocols 12.5 Engineering Noise Controls and Hearing Protector Attenuation 12.6 Hearing Conservation Programs and Standard Threshold Shifts 12.7 Hand-Arm and Whole-Body Vibration

13 Chapter 13: Thermal Stress Assessment & Control

13.1 Wet Bulb Globe Temperature (WBGT) and Heat Stress Indices 13.2 Heat-Related Disorders, Acclimatization, and Work/Rest Regimens 13.3 Cold Stress Evaluation and Wind Chill

14 Chapter 14: Ionizing Radiation Protection

14.1 Ionizing Radiation Physics and Radioactive Decay Kinetics 14.2 Radiation Units, Radiobiology, and Health Effects 14.3 ALARA, Stay-Time, and the Inverse Square Law 14.4 Shielding Physics, Material Selection, and Gamma Constants 14.5 Radiation Detection Instruments and Spectrometry 14.6 Personnel Dosimetry, Dose Limits, and Contamination Surveys

15 Chapter 15: Non-Ionizing Radiation & Laser Safety

15.1 The Non-Ionizing Spectrum and Static/ELF Field Exposures 15.2 Radiofrequency and Microwave Exposure: SAR, Standards, and Surveys 15.3 Ultraviolet, Visible, and Infrared Radiation Hazards 15.4 Laser Safety Classifications and Optical Density Calculations 15.5 Illumination, Lighting Design, and Visual Performance

16 Chapter 16: Non-Engineering Controls & Personal Protective Equipment

16.1 Respiratory Protection Programs and Assigned Protection Factors 16.2 Maximum Use Concentration, Oxygen Deficiency, and Breathing Air 16.3 Particulate Filters, Sorbent Cartridges, and Change Schedules 16.4 Respirator Fit Testing Protocols 16.5 Chemical Protective Clothing and Dermal Exposure Control

17 Chapter 17: Ergonomics & Workstation Design

17.1 Soft-Tissue Biomechanics and WMSD Pathophysiology 17.2 Ergonomic Risk Factors and Their Interaction Effects 17.3 The Revised NIOSH Lifting Equation 17.4 RULA, REBA, the Strain Index, and the ACGIH HAL TLV 17.5 Anthropometry and Workstation Geometry 17.6 VDT Workstations, Hand Tool Design, and Administrative Ergonomics

18 Chapter 18: Work Environments & Industrial Processes

18.1 Welding Fume Emissions, Metal Fume Fever, and Cr(VI)/Manganese Toxicology 18.2 Foundry Operations and Hot Work Fire Prevention 18.3 Vapor Degreasing, Pickling, Electroplating, and Cyanide Baths 18.4 Spray Coatings, Isocyanates, and Semiconductor Manufacturing 18.5 Confined Spaces and High-Hazard Industrial Operations 18.6 Asbestos, Lead, and Silica: Regulated Substance Programs 18.7 Abrasive Blasting and Surface Preparation

19 Chapter 19: IH Program Management & Professional Ethics

19.1 The BGC Code of Ethics: Canons and Enforcement 19.2 Professional Liability, Standard of Care, and Expert Testimony 19.3 Occupational Health & Safety Management Systems (ISO 45001, ANSI Z10) 19.4 Exposure Records Access and Medical Surveillance 19.5 OSHA Injury and Illness Recordkeeping and Enforcement

6.2 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination

Key Takeaways Explain This Topic AI

Absorption route governs internal dose: inhalation delivers agents directly to systemic circulation past first-pass hepatic metabolism, while ingested agents are metabolised by the liver before reaching the systemic compartment.

The volume of distribution (Vd = total body burden / plasma concentration) is an apparent volume, not an anatomical one; a Vd far above total body water indicates extensive tissue or fat sequestration.

Phase I biotransformation (cytochrome P450 oxidation) frequently bioactivates rather than detoxifies — benzene, carbon tetrachloride, and vinyl chloride are all more toxic after metabolism than before.

First-order elimination gives a constant biological half-life and roughly 94% clearance in four half-lives, which is why BEI specimen timing (end of shift, end of workweek, prior to shift) is analyte-specific.

Last updated: August 2026

Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination

Dose-response curves describe what a dose does. Toxicokinetics describes what the body does to the dose — how much of an airborne concentration actually crosses a biological barrier, where it goes, how it is chemically transformed, and how quickly it leaves. Every biological monitoring decision and every shift-adjustment argument on the exam rests on these four processes.

1. Toxicokinetics: Absorption Routes in the Workplace

Toxicokinetics describes the time course of toxicant movement through the body, broken into Absorption , Distribution , Metabolism , and Excretion (ADME) . +-------------------------------------------------------------+

  • | OVERVIEW OF ADME PROCESSES |
  • +-------------------------------------------------------------+
  • | |
  • | ABSORPTION --> Inhalation (Pulmonary, Alveolar) |
  • | Dermal (Stratum Corneum Diffusion) |
  • | Ingestion (GI Tract / Mucociliary Swallowing)|
  • | | |
  • | v |
  • | DISTRIBUTION -> Plasma Albumin Binding |
  • | Apparent Volume of Distribution (Vd) |
  • | Blood-Brain Barrier / Tissue Partitioning |
  • | | |
  • | v |
  • | METABOLISM -> Phase I (CYP450 Functionalization) |
  • | Phase II (Glucuronidation, GST Conjugation)|
  • | | |
  • | v |
  • | EXCRETION --> Renal (Urine), Biliary (Feces), Pulmonary |
  • | First-Order Kinetics: t1/2 = 0.693 / k_el |
  • +-------------------------------------------------------------+
  • Inhalation Absorption & Particle Deposition

Inhalation is the primary route of occupational chemical exposure. The site and extent of airborne deposition depend on physical state and particle size:

Gases and Vapors: Absorption is governed by blood-to-air partition coefficients (Ostwald solubility coefficient). Highly water-soluble gases (NH3, SO2) dissolve rapidly in the moist mucosal lining of the upper respiratory tract. Moderately soluble and lipid-soluble vapors (toluene, methyl chloroform) penetrate directly into the alveolar gas-exchange bed and diffuse across the thin (0.2--0.5 µm) alveolar-capillary membrane.

Particulate Matter (Aerosols): Particle deposition is governed by aerodynamic diameter (dae):

Inhalable Fraction (dae ≤ 100 µm, 50% cut at 100 µm): Deposited in the head airways and nasopharyngeal region via inertial impaction.

Thoracic Fraction (dae ≤ 28 µm, 50% cut at 10 µm): Penetrates past the larynx into the tracheobronchial region via impaction and turbulent sedimentation.

Respirable Fraction (dae ≤ 10 µm, 50% cut at 4.0 µm): Penetrates into unciliated gas-exchange alveolar spaces via gravitational sedimentation and Brownian diffusion (for nanoparticles < 0.5 µm).

Clearance Mechanisms:

Tracheobronchial tree: Mucociliary escalator propels particles upward to the pharynx where they are swallowed into the gastrointestinal tract.

Alveoli: Alveolar macrophages engulf insoluble particles via phagocytosis and transport them to the lymphatic drainage or mucociliary boundary.

Dermal Absorption & Stratum Corneum Flux

The stratum corneum (outermost layer of keratinized, non-viable corneocytes embedded in a lipid-rich intercellular matrix) represents the primary rate-limiting barrier to dermal penetration.

Percutaneous absorption follows Fick's First Law of Steady-State Diffusion : J = K p × Δ C = D × K o w × Δ C h J = K_p \times \Delta C = \frac{D \times K_{ow} \times \Delta C}{h} J = K p ​ × Δ C = h D × K o w ​ × Δ C ​

Where:

  • J = Steady-state dermal flux (mg/(cm²·hr))
  • Kp = Permeability coefficient (cm/hr)
  • D = Diffusion coefficient within stratum corneum (cm²/hr)
  • Kow = Octanol-water partition coefficient (measure of lipophilicity)
  • h = Stratum corneum membrane thickness (cm)
  • Δ C = Concentration gradient across the skin barrier (mg/cm³)

Key Concept: Moderate lipophilicity (Log Kow between 1 and 3) maximizes dermal penetration. Extremely hydrophilic compounds cannot cross the lipid matrix, while extremely lipophilic compounds (Log Kow > 4) dissolve into the stratum corneum but cannot partition out into the aqueous dermal capillary blood flow.

Gastrointestinal Absorption & First-Pass Hepatic Effect

In workplace settings, GI absorption occurs through hand-to-mouth transfer (eating or smoking with contaminated hands) or swallowing mucociliary-cleared inhaled aerosols. Toxicants absorbed from the stomach and intestines enter the hepatic portal system and pass directly to the liver before reaching systemic circulation—subjecting them to hepatic first-pass metabolism (which may detoxify the substance or bioactivate it into toxic metabolites).

2. Toxicokinetics: Distribution and Volume of Distribution (Vd)

Once absorbed into systemic circulation, a toxicant distributes to body tissues based on regional organ blood flow, capillary permeability, tissue affinity, and protein binding.

Plasma Protein Binding

Many xenobiotics bind reversibly to plasma proteins (predominantly albumin for acidic/neutral compounds and α1-acid glycoprotein for basic compounds): Toxicant (Free) + Albumin ⇌ Toxicant-Albumin Complex \text{Toxicant (Free)} + \text{Albumin} \rightleftharpoons \text{Toxicant-Albumin Complex} Toxicant (Free) + Albumin ⇌ Toxicant-Albumin Complex

Only the unbound (free) fraction can cross biological membranes, reach cellular target receptors, undergo hepatic biotransformation, or filter through the renal glomerulus.

Toxicants with high protein binding (> 90%) can be displaced by competing chemicals, causing sharp spikes in free active concentration and unexpected acute toxicity.

Biological Barriers

Blood-Brain Barrier (BBB): Continuous non-fenestrated capillary endothelial cells joined by tight junctions ( zonula occludens ), surrounded by astrocyte end-feet. Protects the central nervous system from polar molecules. Lipophilic, non-ionized toxicants (solvents, methylmercury, organotins) cross freely, whereas polar toxicants are excluded unless transported by specific carrier proteins.

Placental Barrier: Does not prevent the diffusion of most industrial solvents, carbon monoxide, or heavy metals (lead, mercury), allowing significant fetal exposure during critical organogenesis.

Apparent Volume of Distribution (Vd)

Apparent Volume of Distribution (Vd) is the hypothetical volume of fluid into which a total absorbed dose of toxicant would need to be uniformly distributed to achieve the measured plasma concentration at time zero (C0): V d = Total Dose Administered (mg) C 0 (Plasma Concentration, mg/L) \mathbf{V_d = \frac{\text{Total Dose Administered (mg)}}{C_0\text{ (Plasma Concentration, mg/L)}}} V d ​ = C 0 ​ (Plasma Concentration, mg/L) Total Dose Administered (mg) ​ V d ( L/kg ) = V d ( L ) Body Mass (kg) V_d\,(\text{L/kg}) = \frac{V_d\,(\text{L})}{\text{Body Mass (kg)}} V d ​ ( L/kg ) = Body Mass (kg) V d ​ ( L ) ​

Magnitude of Vd Physiological Space Physical Meaning & Toxicological Examples

Low Vd (< 0.1 L/kg or < 7 L) Vascular / Plasma compartment Substance is heavily bound to plasma albumin and does not readily penetrate tissues (e.g., Warfarin, Evans Blue).

Medium Vd (0.1--0.6 L/kg or 15--42 L) Extracellular / Total Body Water Substance distributes freely throughout body water but does not preferentially accumulate in specific organs (e.g., Ethanol, Acetone, Lithium).

High Vd (> 1.0 L/kg, up to 100--1,000 L) Deep tissue / Organ sequestration Substance is heavily sequestered in adipose tissue, liver, or bone; plasma levels are exceedingly low relative to total body burden (e.g., Organochlorine pesticides, PCBs, Lead, Cadmium).

3. Toxicokinetics: Metabolism (Biotransformation)

Biotransformation converts lipophilic xenobiotics (which would otherwise accumulate indefinitely in fatty tissues) into hydrophilic, polar metabolites that are readily excreted in urine or bile. Biotransformation proceeds through two sequential enzymatic phases: +-------------------------------------------------------------+

  • | TWO-PHASE METABOLIC TRANSFORMATION |
  • +-------------------------------------------------------------+
  • | |
  • | Lipophilic Toxicant (Non-polar, high Kow) |
  • | | |
  • | | PHASE I: FUNCTIONALIZATION |
  • | | (CYP450 monooxygenases, oxidation, hydrolysis) |
  • | v |
  • | Functionalized Metabolite (-OH, -COOH, -NH2, -SH) |
  • | *May be bioactivated into toxic reactive intermediate |
  • | | |
  • | | PHASE II: CONJUGATION |
  • | | (Glucuronidation, Sulfation, Glutathione-S-Transf) |
  • | v |
  • | Hydrophilic Conjugate (Polar, water-soluble, ionized) |
  • | | |
  • | +---> Rapid Excretion (Urine via kidney, Bile/Feces) |
  • +-------------------------------------------------------------+
  • Phase I Reactions: Functionalization

Enzyme Systems: Cytochrome P450 monooxygenase superfamily (CYP450) located primarily in the smooth endoplasmic reticulum (microsomes) of hepatocytes (e.g., CYP1A2, CYP2E1, CYP3A4).

Mechanism: Catalyzes the insertion of one atom of molecular oxygen into the substrate (R-H + O2 + NADPH + H⁺ → R-OH + H2O + NADP⁺).

Reaction Types: Hydroxylation, dealkylation, epoxidation, dehalogenation, reduction, and hydrolysis.

Bioactivation (Toxification): While Phase I generally prepares molecules for detoxification, it frequently bioactivates parent compounds into highly reactive, electrophilic intermediates (e.g., conversion of carbon tetrachloride into trichloromethyl radical ·CCl3 via CYP2E1; conversion of benzene to benzene oxide; epoxidation of benzo[a]pyrene).

Phase II Reactions: Conjugation

Mechanism: Endogenous hydrophilic molecules are covalently coupled to functional groups (-OH, -COOH, -NH2, -SH) introduced during Phase I.

Key Conjugation Pathways:

Glucuronidation: Catalyzed by UDP-glucuronosyltransferases (UGTs); transfers glucuronic acid from UDP-glucuronic acid (UDPGA). Quantitatively the most common clearance pathway.

Sulfation: Catalyzed by sulfotransferases (SULTs); transfers sulfate from 3'-phosphoadenosine-5'-phosphosulfate (PAPS). High affinity but low capacity (easily saturated).

Glutathione S-Conjugation: Catalyzed by Glutathione S-Transferases (GSTs); couples the tripeptide glutathione (GSH) to reactive electrophilic intermediates, neutralizing cellular attack. Glutathione conjugates are further cleaved in the kidney into mercapturic acids (e.g., S-phenylmercapturic acid from benzene) and excreted in urine.

Acetylation: Catalyzed by N-acetyltransferases (NAT1, NAT2); transfers acetyl groups to aromatic amines (e.g., benzidine, 2-naphthylamine). Genetic polymorphisms ("slow acetylators") increase bladder cancer vulnerability.

  • 4. Toxicokinetics: Elimination Kinetics & Biological Half-Life
  • First-Order vs. Zero-Order Elimination Kinetics

First-Order Kinetics (Linear Elimination):

The rate of elimination is directly proportional to the plasma concentration (-dC/dt = kel C).

A constant fraction of the toxicant is eliminated per unit time.

Clearance pathways are operating below saturation capacity (the typical scenario for most workplace chemical exposures).

Zero-Order Kinetics (Saturable / Capacity-Limited Elimination):

The rate of elimination is constant and independent of concentration (-dC/dt = k0).

A constant absolute amount of toxicant is eliminated per unit time because metabolic or excretory enzyme systems are completely saturated (e.g., Ethanol metabolism via alcohol dehydrogenase at normal intoxicating doses; high-dose Salicylates). +-------------------------------------------------------------+

  • | FIRST-ORDER VS. ZERO-ORDER ELIMINATION |
  • +-------------------------------------------------------------+
  • | Concentration (Linear) Concentration (Semi-Log) |
  • | | | |
  • | | \\ First-Order (Exponential) | |\ |
  • | | \\ | | \\ First-Order (Linear)|
  • | | \\ | | \\ |
  • | | ----- Zero-Order (Linear) | | --- Zero-Order |
  • | 0 +---------------------> 0 +----------------------> |
  • | 0 Time 0 Time |
  • +-------------------------------------------------------------+
  • Mathematical Formulation of First-Order Elimination

For a substance following first-order kinetics: ln ⁡ ( C t ) = ln ⁡ ( C 0 ) − k e l ⋅ t ⟺ C t = C 0 ⋅ e − k e l ⋅ t \ln(C_t) = \ln(C_0) - k_{el} \cdot t \quad \Longleftrightarrow \quad C_t = C_0 \cdot e^{-k_{el} \cdot t} ln ( C t ​ ) = ln ( C 0 ​ ) − k e l ​ ⋅ t ⟺ C t ​ = C 0 ​ ⋅ e − k e l ​ ⋅ t

Where:

  • Ct = Plasma concentration at time t
  • C0 = Initial plasma concentration at time zero
  • kel = Elimination rate constant (hr⁻¹ or day⁻¹)
  • t = Elapsed time (hours or days)
  • Elimination Half-Life (t(1/2))

The biological half-life (t(1/2)) is the time required for the systemic concentration of a toxicant to decrease by exactly 50%: t 1 / 2 = ln ⁡ ( 2 ) k e l = 0.69315 k e l ⟺ k e l = 0.69315 t 1 / 2 \mathbf{t_{1/2} = \frac{\ln(2)}{k_{el}} = \frac{0.69315}{k_{el}} \quad \Longleftrightarrow \quad k_{el} = \frac{0.69315}{t_{1/2}}} t 1/2 ​ = k el ​ ln ( 2 ) ​ = k el ​ 0.69315 ​ ⟺ k el ​ = t 1/2 ​ 0.69315 ​

Systemic Clearance (CL)

Total body clearance is the volume of plasma completely cleared of toxicant per unit time: C L = k e l × V d = 0.693 × V d t 1 / 2 CL = k_{el} \times V_d = \frac{0.693 \times V_d}{t_{1/2}} C L = k e l ​ × V d ​ = t 1/2 ​ 0.693 × V d ​ ​

The 5 Half-Lives Rule in Industrial Hygiene

During constant occupational exposure (e.g., an 8-hour shift) or post-exposure biological washout, the approach to steady-state (Css) or total elimination follows the exponential rule:

  • Number of Half-Lives (n) % Steady-State Achieved % Parent Compound Eliminated
  • 1 × t(1/2) 50.0% 50.0%
  • 2 × t(1/2) 75.0% 75.0%
  • 3 × t(1/2) 87.5% 87.5%
  • 4 × t(1/2) 93.75% 93.75%
  • 5 × t(1/2) 96.875% (Nominal Completion) 96.875% (Nominal Clearance)
  • 7 × t(1/2) 99.2% 99.2%

Exam Key Concept: When scheduling biological monitoring samples, substances with t(1/2) < 5 hours reflect same-day shift exposures and must be collected at End of Shift . Substances with t(1/2) ≈ 15--40 hours accumulate over the week and must be collected at End of Workweek . Substances with t(1/2) > 1 year (e.g., Cadmium, Lead) reflect cumulative lifetime burden and can be collected at Discretionary / Any Time .

  • 5. Worked Step-by-Step Calculation Examples
  • Worked Example 5.1.1: Elimination Rate Constant and Biological Half-Life Calculation

Problem: A worker accidentally ingests an industrial solvent. Serial venous blood samples indicate a plasma concentration of 80.0 mg/L at 12:00 PM (time zero) and 20.0 mg/L at 8:00 PM (8 hours later). Assuming the solvent follows first-order single-compartment elimination kinetics:

Calculate the elimination rate constant (kel).

Calculate the biological half-life (t(1/2)).

Determine the expected plasma concentration at 12:00 AM (midnight, 12 hours after the initial measurement).

Solution Steps:

Calculate the elimination rate constant (kel): ln ⁡ ( C t ) = ln ⁡ ( C 0 ) − k e l ⋅ t ⟹ k e l = ln ⁡ ( C 0 ) − ln ⁡ ( C t ) t \ln(C_t) = \ln(C_0) - k_{el} \cdot t \implies k_{el} = \frac{\ln(C_0) - \ln(C_t)}{t} ln ( C t ​ ) = ln ( C 0 ​ ) − k e l ​ ⋅ t ⟹ k e l ​ = t ln ( C 0 ​ ) − ln ( C t ​ ) ​ k e l = ln ⁡ ( 80.0 ) − ln ⁡ ( 20.0 ) 8 hr = 4.3820 − 2.9957 8 hr = 1.3863 8 hr = 0.1733 hr − 1 k_{el} = \frac{\ln(80.0) - \ln(20.0)}{8\,\text{hr}} = \frac{4.3820 - 2.9957}{8\,\text{hr}} = \frac{1.3863}{8\,\text{hr}} = 0.1733\,\text{hr}^{-1} k e l ​ = 8 hr ln ( 80.0 ) − ln ( 20.0 ) ​ = 8 hr 4.3820 − 2.9957 ​ = 8 hr 1.3863 ​ = 0.1733 hr − 1

Calculate the biological half-life (t(1/2)): t 1 / 2 = 0.69315 k e l = 0.69315 0.1733 hr − 1 = 4.00 hours t_{1/2} = \frac{0.69315}{k_{el}} = \frac{0.69315}{0.1733\,\text{hr}^{-1}} = 4.00\,\text{hours} t 1/2 ​ = k e l ​ 0.69315 ​ = 0.1733 hr − 1 0.69315 ​ = 4.00 hours

Calculate concentration at t = 12 hours:

Note that 12 hours = 3 half-lives (12 / 4 = 3).

After 3 half-lives: C12 = C0 × (0.5)³ = 80.0 × 0.125 = 10.0 mg/L.

Using the exponential formula directly: C 12 = 80.0 ⋅ e − ( 0.1733 × 12 ) = 80.0 ⋅ e − 2.0796 = 80.0 × 0.1250 = 10.0 mg/L C_{12} = 80.0 \cdot e^{-(0.1733 \times 12)} = 80.0 \cdot e^{-2.0796} = 80.0 \times 0.1250 = 10.0\,\text{mg/L} C 12 ​ = 80.0 ⋅ e − ( 0.1733 × 12 ) = 80.0 ⋅ e − 2.0796 = 80.0 × 0.1250 = 10.0 mg/L

Result: The elimination rate constant is 0.173 hr⁻¹ , the biological half-life is 4.0 hours , and the plasma concentration at midnight will be 10.0 mg/L .

Worked Example 5.1.2: Reference Dose (RfD) Derivation Using BMDL10 and Uncertainty Factors

Problem: A 90-day subchronic oral toxicity study of a novel industrial plasticizer in Sprague-Dawley rats evaluates renal tubular damage. Benchmark dose modeling determines a BMDL10 of 15.0 mg/kg/day. Toxicologists assign the following uncertainty factors: Interspecies variability (10×), Intraspecies human variability (10×), Subchronic-to-chronic extrapolation (10×), and Database completeness (1×).

Calculate the acceptable Human Reference Dose (RfD) in mg/kg/day and µg/kg/day.

For an adult worker weighing 70 kg, what is the maximum acceptable daily intake (in milligrams/day)?

Solution Steps:

Calculate the Reference Dose (RfD): ∏ UF = U F A × U F H × U F S × U F D = 10 × 10 × 10 × 1 = 1 , 000 \prod \text{UF} = UF_A \times UF_H \times UF_S \times UF_D = 10 \times 10 \times 10 \times 1 = 1,000 ∏ UF = U F A ​ × U F H ​ × U F S ​ × U F D ​ = 10 × 10 × 10 × 1 = 1 , 000 R f D = BMDL 10 ∏ UF = 15.0 mg/kg/day 1 , 000 = 0.015 mg/kg/day = 15.0 μ g/kg/day RfD = \frac{\text{BMDL}_{10}}{\prod \text{UF}} = \frac{15.0\,\text{mg/kg/day}}{1,000} = 0.015\,\text{mg/kg/day} = 15.0\,\mu\text{g/kg/day} R f D = ∏ UF BMDL 10 ​ ​ = 1 , 000 15.0 mg/kg/day ​ = 0.015 mg/kg/day = 15.0 μ g/kg/day

Calculate maximum acceptable daily intake for a 70 kg worker: Daily Intake = R f D × Body Weight = 0.015 mg/kg/day × 70 kg = 1.05 mg/day \text{Daily Intake} = RfD \times \text{Body Weight} = 0.015\,\text{mg/kg/day} \times 70\,\text{kg} = 1.05\,\text{mg/day} Daily Intake = R f D × Body Weight = 0.015 mg/kg/day × 70 kg = 1.05 mg/day

Result: The derived human RfD is 0.015 mg/kg/day (15.0 µg/kg/day) , corresponding to a maximum allowable daily intake of 1.05 mg/day for a 70 kg adult.

Worked Example 5.1.3: Apparent Volume of Distribution (Vd) Calculation and Interpretation

Problem: A research worker receives an accidental intravenous injection of 350 mg of a lipid-soluble organic compound. An initial blood sample drawn immediately post-distribution reveals a plasma concentration of 0.050 mg/L. The worker weighs 70.0 kg.

Calculate the apparent Volume of Distribution (Vd) in liters (L).

Calculate the normalized Vd in L/kg.

Interpret what this numerical value indicates regarding tissue distribution.

Solution Steps:

Calculate total Vd in Liters: V d = Total Dose (mg) C 0 ( mg/L ) = 350 mg 0.050 mg/L = 7 , 000 Liters V_d = \frac{\text{Total Dose (mg)}}{C_0\,(\text{mg/L})} = \frac{350\,\text{mg}}{0.050\,\text{mg/L}} = 7,000\,\text{Liters} V d ​ = C 0 ​ ( mg/L ) Total Dose (mg) ​ = 0.050 mg/L 350 mg ​ = 7 , 000 Liters

Calculate normalized Vd in L/kg: V d ( L/kg ) = 7 , 000 L 70.0 kg = 100 L/kg V_d\,(\text{L/kg}) = \frac{7,000\,\text{L}}{70.0\,\text{kg}} = 100\,\text{L/kg} V d ​ ( L/kg ) = 70.0 kg 7 , 000 L ​ = 100 L/kg

Toxicological Interpretation:

Total body water in a 70 kg human is approximately 42 L (0.6 L/kg).

A Vd of 7,000 L (100 L/kg) far exceeds total anatomical body volume. This demonstrates that the toxicant is extremely lipophilic and overwhelmingly sequestered in extravascular tissues (such as adipose tissue, liver, or peripheral lipid membranes) , leaving only an infinitesimal fraction in circulating plasma.